Skip to search formSkip to main contentSkip to account menu

idalopirdine

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson’s disease
Falls in patients with Parkinson’s disease (PD) are associated with cognitive, specifically attentional impairments and with… 
2019
2019
Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease.
This open-label extension study evaluated the long-term safety and tolerability of idalopirdine 60 mg/day as adjunctive therapy… 
2019
2019
Correction to: Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson’s disease
After publication of this paper, the authors determined that the “Acknowledgments” section was omitted. Below is the… 
2018
2018
Idalopirdine for Alzheimer Disease
Although anticholinesterase medications and memantine have been widely used for the treatment of Alzheimer disease (AD), they are… 
2017
2017
The 5-HT6 receptor antagonist idalopirdine potentiates the effects of donepezil on gamma oscillations in the frontal cortex of anesthetized and awake rats without affecting sleep-wake architecture
2017
2017
Idalopirdine (LY483518, SGS518, Lu AE 58054) in Alzheimer disease: never change a winning team and do not build exclusively on surrogates. Lessons Learned from Drug Development Trials
The effect of Acetylcholinesterase inhibition on Alzheimer’s disease is modest. Augmentation strategies are thus whished for and… 
2016
2016
A 5-HT6 Antagonist as Adjunctive Therapy to Cholinesterase Inhibitors in Patients with Mild-to-Moderate Alzheimer's Disease: Idalopirdine in Phase III
2016
2016
A 5-HT6 Antagonist as Adjunctive Therapy to Cholinesterase Inhibitors in Patients with Mild-to-Moderate Alzheimer’s Disease: Idalopirdine in Phase III (PL02.006)
Objective: To assess the efficacy and safety of idalopirdine as adjunctive therapy to cholinesterase inhibitors in patients with… 
Review
2015
Review
2015
Idalopirdine as a treatment for Alzheimer’s disease
Introduction: Alzheimer’s disease (AD) is the most common cause of dementia in the elderly. Pharmacological treatment of AD… 
2014
2014
Idalopirdine for Alzheimer's disease: written in the stars
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)